Table 1.
Neoadjuvant trastuzumab and chemotherapy in 205 patients with operable or locally advanced HER2-positive breast cancer
| Regimens | N (%) |
|---|---|
| Trastuzumab concomitant to taxanes | 123 (60.0) |
| After anthra-based regimens | |
| EC/FEC → Trastuzumab + taxanes | 65 (31.7) |
| EC→ Trastuzumab + docetaxel + carboplatin or capecitabine | 35 (17.1) |
| TEC → Trastuzumab + paclitaxel | 2 (0.1) |
| NPLDoxo + docetaxel→ Trastuzumab + docetaxel | 1 (0.5) |
| Before anthra-based regimens | |
| Trastuzumab + paclitaxel → EC | 2 (0.10) |
| Nonanthra-based regimens | |
| Trastuzumab + taxanes | 14 (6.9) |
| MTX + docetaxel → Trastuzumab + docetaxel | 3 (1.5) |
| Trastuzumab + docetaxel + carboplatin | 1 (0.5) |
| Trastuzumab concomitant to anthracyclines and taxanes | 77 (37.57) |
| Trastuzumab + taxanes → Trastuzumab + FEC or EC | 67 (32.7) |
| Trastuzumab + NPLDoxo + CTX→ Trastuzumab + paclitaxel + carboplatin | 5 (2.4) |
| Trastuzumab + FEC or E → Trastuzumab + taxanes | 5 (2.4) |
| Trastuzumab concomitant to other schemes | 5 (2.43) |
EC Epirubicin and cyclophosphamide, FEC fluorouracil, epirubicin and cyclophosphamide, Taxanes paclitaxel or docetaxel, TEC docetaxel, epirubicin and cyclophosphamide, NPLDoxo nonpegylated liposomal doxorubicin, MTX methotrexate, CTX cyclophosphamide, E epirubicin